Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE) Meeting Abstract

  

Authors:	Smith, M. R.; Sweeney, C.; Rathkopf, D. E.; Scher, H. I.; Logothetis, C.; George, D. J.; Higano, C. S.; Yu, E. Y.; Harzstark, A. L.; Small, E. J.; Sartor, A. O.; Gordon, M. S.; Vogelzang, N. J.; Smith, D. C.; Hussain, M.; De Bono, J. S.; Haas, N. B.; Scheffold, C.; Lee, Y.; Corn, P. G.
Abstract Title:	Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)
Meeting Title:	48th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	30
Issue:	15 Suppl.
Meeting Dates:	2012 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2012-05-20
Language:	English
ACCESSION:	WOS:000318009802576
PROVIDER:	wos
DOI:	10.1200/jco.2012.30.15_suppl.4513
Notes:	Meeting Abstract: 4513 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/152181